Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 104 entries
Sorted by: Best Match Show Resources per page
Temporal variation in antibiotic environments slows down resistance evolution in pathogenic Pseudomonas aeruginosa.

Evolutionary applications

Roemhild R, Barbosa C, Beardmore RE, Jansen G, Schulenburg H.
PMID: 26640520
Evol Appl. 2015 Dec;8(10):945-55. doi: 10.1111/eva.12330. Epub 2015 Oct 07.

Antibiotic resistance is a growing concern to public health. New treatment strategies may alleviate the situation by slowing down the evolution of resistance. Here, we evaluated sequential treatment protocols using two fully independent laboratory-controlled evolution experiments with the human...

Cite
Roemhild R, Barbosa C, Beardmore RE, et al. Temporal variation in antibiotic environments slows down resistance evolution in pathogenic Pseudomonas aeruginosa. Evol Appl. 2015;8(10):945-55doi: 10.1111/eva.12330.
Roemhild, R., Barbosa, C., Beardmore, R. E., Jansen, G., & Schulenburg, H. (2015). Temporal variation in antibiotic environments slows down resistance evolution in pathogenic Pseudomonas aeruginosa. Evolutionary applications, 8(10), 945-55. https://doi.org/10.1111/eva.12330
Roemhild, Roderich, et al. "Temporal variation in antibiotic environments slows down resistance evolution in pathogenic Pseudomonas aeruginosa." Evolutionary applications vol. 8,10 (2015): 945-55. doi: https://doi.org/10.1111/eva.12330
Roemhild R, Barbosa C, Beardmore RE, Jansen G, Schulenburg H. Temporal variation in antibiotic environments slows down resistance evolution in pathogenic Pseudomonas aeruginosa. Evol Appl. 2015 Dec;8(10):945-55. doi: 10.1111/eva.12330. Epub 2015 Oct 07. PMID: 26640520; PMCID: PMC4662347.
Copy Download .nbib Format: NLM
WITHDRAWN: Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem.

Diagnostic microbiology and infectious disease

Jones RN, Sader HS, Fritsche TR, Janechek MJ.
PMID: 17919870
Diagn Microbiol Infect Dis. 2007 Oct 04; doi: 10.1016/j.diagmicrobio.2007.09.009. Epub 2007 Oct 04.

This article has been withdrawn consistent with Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). The Publisher apologizes for any inconvenience this may cause.

Cite
Jones RN, Sader HS, Fritsche TR, et al. WITHDRAWN: Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. Diagn Microbiol Infect Dis. 2007;doi: 10.1016/j.diagmicrobio.2007.09.009.
Jones, R. N., Sader, H. S., Fritsche, T. R., & Janechek, M. J. (2007). WITHDRAWN: Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. Diagnostic microbiology and infectious disease, . https://doi.org/10.1016/j.diagmicrobio.2007.09.009
Jones, Ronald N, et al. "WITHDRAWN: Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem." Diagnostic microbiology and infectious disease vol. (2007). doi: https://doi.org/10.1016/j.diagmicrobio.2007.09.009
Jones RN, Sader HS, Fritsche TR, Janechek MJ. WITHDRAWN: Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. Diagn Microbiol Infect Dis. 2007 Oct 04; doi: 10.1016/j.diagmicrobio.2007.09.009. Epub 2007 Oct 04. PMID: 17919870.
Copy Download .nbib Format: NLM
Evaluation of the highly sensitive Roche thyroglobulin II assay and establishment of a reference limit for thyroglobulin-negative patient samples.

Practical laboratory medicine

Rotteveel-de Groot DM, Ross HA, Janssen MJR, Netea-Maier RT, Oosting JD, Sweep FCGJ, van Herwaarden AE.
PMID: 28856198
Pract Lab Med. 2016 Mar 03;5:6-13. doi: 10.1016/j.plabm.2016.02.001. eCollection 2016 Aug 01.

OBJECTIVES: Thyroglobulin (Tg) measurements are used to monitor for residual thyroid tissue in patients with differentiated thyroid cancer (DTC) after thyroidectomy and radioiodine ablative therapy. In recent years highly sensitive Tg assays have been developed. In this study the...

Cite
Rotteveel-de Groot DM, Ross HA, Janssen MJR, et al. Evaluation of the highly sensitive Roche thyroglobulin II assay and establishment of a reference limit for thyroglobulin-negative patient samples. Pract Lab Med. 2016;5:6-13doi: 10.1016/j.plabm.2016.02.001.
Rotteveel-de Groot, D. M., Ross, H. A., Janssen, M. J. R., Netea-Maier, R. T., Oosting, J. D., Sweep, F. C. G. J., & van Herwaarden, A. E. (2016). Evaluation of the highly sensitive Roche thyroglobulin II assay and establishment of a reference limit for thyroglobulin-negative patient samples. Practical laboratory medicine, 56-13. https://doi.org/10.1016/j.plabm.2016.02.001
Rotteveel-de Groot, Dorien M, et al. "Evaluation of the highly sensitive Roche thyroglobulin II assay and establishment of a reference limit for thyroglobulin-negative patient samples." Practical laboratory medicine vol. 5 (2016): 6-13. doi: https://doi.org/10.1016/j.plabm.2016.02.001
Rotteveel-de Groot DM, Ross HA, Janssen MJR, Netea-Maier RT, Oosting JD, Sweep FCGJ, van Herwaarden AE. Evaluation of the highly sensitive Roche thyroglobulin II assay and establishment of a reference limit for thyroglobulin-negative patient samples. Pract Lab Med. 2016 Mar 03;5:6-13. doi: 10.1016/j.plabm.2016.02.001. eCollection 2016 Aug 01. PMID: 28856198; PMCID: PMC5574515.
Copy Download .nbib Format: NLM
Widening the net: a literature review of antimicrobial agents with potential suitability for outpatient parenteral antimicrobial therapy services-the importance of storage and stability.

European journal of hospital pharmacy : science and practice

Jenkins A, Shanu S, Jamieson C, Santillo M.
PMID: 34862256
Eur J Hosp Pharm. 2021 Dec 03; doi: 10.1136/ejhpharm-2021-002937. Epub 2021 Dec 03.

OBJECTIVES: Outpatient parenteral antimicrobial therapy (OPAT) services using continuous infusions (CIs) of antimicrobial agents in elastomeric devices require evidence of acceptable stability of the agent over the infusion period. A period of refrigerated storage of filled devices, followed by...

Cite
Jenkins A, Shanu S, Jamieson C, et al. Widening the net: a literature review of antimicrobial agents with potential suitability for outpatient parenteral antimicrobial therapy services-the importance of storage and stability. Eur J Hosp Pharm. 2021;doi: 10.1136/ejhpharm-2021-002937.
Jenkins, A., Shanu, S., Jamieson, C., & Santillo, M. (2021). Widening the net: a literature review of antimicrobial agents with potential suitability for outpatient parenteral antimicrobial therapy services-the importance of storage and stability. European journal of hospital pharmacy : science and practice, . https://doi.org/10.1136/ejhpharm-2021-002937
Jenkins, Abi, et al. "Widening the net: a literature review of antimicrobial agents with potential suitability for outpatient parenteral antimicrobial therapy services-the importance of storage and stability." European journal of hospital pharmacy : science and practice vol. (2021). doi: https://doi.org/10.1136/ejhpharm-2021-002937
Jenkins A, Shanu S, Jamieson C, Santillo M. Widening the net: a literature review of antimicrobial agents with potential suitability for outpatient parenteral antimicrobial therapy services-the importance of storage and stability. Eur J Hosp Pharm. 2021 Dec 03; doi: 10.1136/ejhpharm-2021-002937. Epub 2021 Dec 03. PMID: 34862256.
Copy Download .nbib Format: NLM
Risk factors for type 1 and type 2 myocardial infarction.

European heart journal

Wereski R, Kimenai DM, Bularga A, Taggart C, Lowe DJ, Mills NL, Chapman AR.
PMID: 34431993
Eur Heart J. 2022 Jan 13;43(2):127-135. doi: 10.1093/eurheartj/ehab581.

AIMS: Whilst the risk factors for type 1 myocardial infarction due to atherosclerotic plaque rupture and thrombosis are established, our understanding of the factors that predispose to type 2 myocardial infarction during acute illness is still emerging. Our aim...

Cite
Wereski R, Kimenai DM, Bularga A, et al. Risk factors for type 1 and type 2 myocardial infarction. Eur Heart J. 2022;43(2):127-135doi: 10.1093/eurheartj/ehab581.
Wereski, R., Kimenai, D. M., Bularga, A., Taggart, C., Lowe, D. J., Mills, N. L., & Chapman, A. R. (2022). Risk factors for type 1 and type 2 myocardial infarction. European heart journal, 43(2), 127-135. https://doi.org/10.1093/eurheartj/ehab581
Wereski, Ryan, et al. "Risk factors for type 1 and type 2 myocardial infarction." European heart journal vol. 43,2 (2022): 127-135. doi: https://doi.org/10.1093/eurheartj/ehab581
Wereski R, Kimenai DM, Bularga A, Taggart C, Lowe DJ, Mills NL, Chapman AR. Risk factors for type 1 and type 2 myocardial infarction. Eur Heart J. 2022 Jan 13;43(2):127-135. doi: 10.1093/eurheartj/ehab581. PMID: 34431993.
Copy Download .nbib Format: NLM
Bacteriological and histopathological findings in cetaceans that stranded in the Philippines from 2017 to 2018.

PloS one

Obusan MCM, Caras JAA, Lumang LSL, Calderon EJS, Villanueva RMD, Salibay CC, Siringan MAT, Rivera WL, Masangkay JS, Aragones LV.
PMID: 34762695
PLoS One. 2021 Nov 11;16(11):e0243691. doi: 10.1371/journal.pone.0243691. eCollection 2021.

The relatively high frequency of marine mammal stranding events in the Philippines provide many research opportunities. A select set of stranders (n = 21) from 2017 to 2018 were sampled for bacteriology and histopathology. Pertinent tissues and bacteria were...

Cite
Obusan MCM, Caras JAA, Lumang LSL, et al. Bacteriological and histopathological findings in cetaceans that stranded in the Philippines from 2017 to 2018. PLoS One. 2021;16(11):e0243691doi: 10.1371/journal.pone.0243691.
Obusan, M. C. M., Caras, J. A. A., Lumang, L. S. L., Calderon, E. J. S., Villanueva, R. M. D., Salibay, C. C., Siringan, M. A. T., Rivera, W. L., Masangkay, J. S., & Aragones, L. V. (2021). Bacteriological and histopathological findings in cetaceans that stranded in the Philippines from 2017 to 2018. PloS one, 16(11), e0243691. https://doi.org/10.1371/journal.pone.0243691
Obusan, Marie Christine M, et al. "Bacteriological and histopathological findings in cetaceans that stranded in the Philippines from 2017 to 2018." PloS one vol. 16,11 (2021): e0243691. doi: https://doi.org/10.1371/journal.pone.0243691
Obusan MCM, Caras JAA, Lumang LSL, Calderon EJS, Villanueva RMD, Salibay CC, Siringan MAT, Rivera WL, Masangkay JS, Aragones LV. Bacteriological and histopathological findings in cetaceans that stranded in the Philippines from 2017 to 2018. PLoS One. 2021 Nov 11;16(11):e0243691. doi: 10.1371/journal.pone.0243691. eCollection 2021. PMID: 34762695; PMCID: PMC8584710.
Copy Download .nbib Format: NLM
Risk factors for type 1 and type 2 myocardial infarction.

European heart journal

Wereski R, Kimenai DM, Bularga A, Taggart C, Lowe DJ, Mills NL, Chapman AR.
PMID: 34431993
Eur Heart J. 2022 Jan 13;43(2):127-135. doi: 10.1093/eurheartj/ehab581.

AIMS: Whilst the risk factors for type 1 myocardial infarction due to atherosclerotic plaque rupture and thrombosis are established, our understanding of the factors that predispose to type 2 myocardial infarction during acute illness is still emerging. Our aim...

Cite
Wereski R, Kimenai DM, Bularga A, et al. Risk factors for type 1 and type 2 myocardial infarction. Eur Heart J. 2022;43(2):127-135doi: 10.1093/eurheartj/ehab581.
Wereski, R., Kimenai, D. M., Bularga, A., Taggart, C., Lowe, D. J., Mills, N. L., & Chapman, A. R. (2022). Risk factors for type 1 and type 2 myocardial infarction. European heart journal, 43(2), 127-135. https://doi.org/10.1093/eurheartj/ehab581
Wereski, Ryan, et al. "Risk factors for type 1 and type 2 myocardial infarction." European heart journal vol. 43,2 (2022): 127-135. doi: https://doi.org/10.1093/eurheartj/ehab581
Wereski R, Kimenai DM, Bularga A, Taggart C, Lowe DJ, Mills NL, Chapman AR. Risk factors for type 1 and type 2 myocardial infarction. Eur Heart J. 2022 Jan 13;43(2):127-135. doi: 10.1093/eurheartj/ehab581. PMID: 34431993; PMCID: PMC8757580.
Copy Download .nbib Format: NLM
Implementation of an early rule-out pathway for myocardial infarction using a high-sensitivity cardiac troponin T assay.

Open heart

Sandeman D, Syed MBJ, Kimenai DM, Lee KK, Anand A, Joshi SS, Dinnel L, Wenham PR, Campbell K, Jarvie M, Galloway D, Anderson M, Roy B, Andrews JPM, Strachan FE, Ferry AV, Chapman AR, Elsby S, Francis M, Cargill R, Shah ASV, Mills NL.
PMID: 34824100
Open Heart. 2021 Nov;8(2). doi: 10.1136/openhrt-2021-001769.

OBJECTIVES: Patients with suspected acute coronary syndrome and high-sensitivity cardiac troponin (hs-cTn) concentrations below the limit of detection at presentation are low risk. We aim to determine whether implementing this approach facilitates the safe early discharge of patients.METHODS: In...

Cite
Sandeman D, Syed MBJ, Kimenai DM, et al. Implementation of an early rule-out pathway for myocardial infarction using a high-sensitivity cardiac troponin T assay. Open Heart. 2021;8(2)doi: 10.1136/openhrt-2021-001769.
Sandeman, D., Syed, M. B. J., Kimenai, D. M., Lee, K. K., Anand, A., Joshi, S. S., Dinnel, L., Wenham, P. R., Campbell, K., Jarvie, M., Galloway, D., Anderson, M., Roy, B., Andrews, J. P. M., Strachan, F. E., Ferry, A. V., Chapman, A. R., Elsby, S., Francis, M., Cargill, R., Shah, A. S. V., & Mills, N. L. (2021). Implementation of an early rule-out pathway for myocardial infarction using a high-sensitivity cardiac troponin T assay. Open heart, 8(2), . https://doi.org/10.1136/openhrt-2021-001769
Sandeman, Dennis, et al. "Implementation of an early rule-out pathway for myocardial infarction using a high-sensitivity cardiac troponin T assay." Open heart vol. 8,2 (2021). doi: https://doi.org/10.1136/openhrt-2021-001769
Sandeman D, Syed MBJ, Kimenai DM, Lee KK, Anand A, Joshi SS, Dinnel L, Wenham PR, Campbell K, Jarvie M, Galloway D, Anderson M, Roy B, Andrews JPM, Strachan FE, Ferry AV, Chapman AR, Elsby S, Francis M, Cargill R, Shah ASV, Mills NL. Implementation of an early rule-out pathway for myocardial infarction using a high-sensitivity cardiac troponin T assay. Open Heart. 2021 Nov;8(2). doi: 10.1136/openhrt-2021-001769. PMID: 34824100; PMCID: PMC8627412.
Copy Download .nbib Format: NLM
Sex Differences in Cardiac Troponin I and T and the Prediction of Cardiovascular Events in the General Population.

Clinical chemistry

Kimenai DM, Shah ASV, McAllister DA, Lee KK, Tsanas A, Meex SJR, Porteous DJ, Hayward C, Campbell A, Sattar N, Mills NL, Welsh P.
PMID: 34240125
Clin Chem. 2021 Oct 01;67(10):1351-1360. doi: 10.1093/clinchem/hvab109.

BACKGROUND: Cardiac troponin concentrations differ in women and men, but how this influences risk prediction and whether a sex-specific approach is required is unclear. We evaluated whether sex influences the predictive ability of cardiac troponin I and T for...

Cite
Kimenai DM, Shah ASV, McAllister DA, et al. Sex Differences in Cardiac Troponin I and T and the Prediction of Cardiovascular Events in the General Population. Clin Chem. 2021;67(10):1351-1360doi: 10.1093/clinchem/hvab109.
Kimenai, D. M., Shah, A. S. V., McAllister, D. A., Lee, K. K., Tsanas, A., Meex, S. J. R., Porteous, D. J., Hayward, C., Campbell, A., Sattar, N., Mills, N. L., & Welsh, P. (2021). Sex Differences in Cardiac Troponin I and T and the Prediction of Cardiovascular Events in the General Population. Clinical chemistry, 67(10), 1351-1360. https://doi.org/10.1093/clinchem/hvab109
Kimenai, Dorien M, et al. "Sex Differences in Cardiac Troponin I and T and the Prediction of Cardiovascular Events in the General Population." Clinical chemistry vol. 67,10 (2021): 1351-1360. doi: https://doi.org/10.1093/clinchem/hvab109
Kimenai DM, Shah ASV, McAllister DA, Lee KK, Tsanas A, Meex SJR, Porteous DJ, Hayward C, Campbell A, Sattar N, Mills NL, Welsh P. Sex Differences in Cardiac Troponin I and T and the Prediction of Cardiovascular Events in the General Population. Clin Chem. 2021 Oct 01;67(10):1351-1360. doi: 10.1093/clinchem/hvab109. PMID: 34240125; PMCID: PMC8486023.
Copy Download .nbib Format: NLM
A Case of an 80-Year-Old Man with Empyema and Psoas Abscess.

Case reports in emergency medicine

Sakurai M, Nagasawa H, Takeuchi I, Yanagawa Y.
PMID: 33163240
Case Rep Emerg Med. 2020 Oct 24;2020:8895785. doi: 10.1155/2020/8895785. eCollection 2020.

An 80-year-old man with flu symptoms collapsed at his house and had a backache worsened over time. His family called for an ambulance. On arrival, chest X-ray showed reduced permeability of the right lung field, and truncal computed tomography...

Cite
Sakurai M, Nagasawa H, Takeuchi I, et al. A Case of an 80-Year-Old Man with Empyema and Psoas Abscess. Case Rep Emerg Med. 2020;2020:8895785doi: 10.1155/2020/8895785.
Sakurai, M., Nagasawa, H., Takeuchi, I., & Yanagawa, Y. (2020). A Case of an 80-Year-Old Man with Empyema and Psoas Abscess. Case reports in emergency medicine, 20208895785. https://doi.org/10.1155/2020/8895785
Sakurai, Mikio, et al. "A Case of an 80-Year-Old Man with Empyema and Psoas Abscess." Case reports in emergency medicine vol. 2020 (2020): 8895785. doi: https://doi.org/10.1155/2020/8895785
Sakurai M, Nagasawa H, Takeuchi I, Yanagawa Y. A Case of an 80-Year-Old Man with Empyema and Psoas Abscess. Case Rep Emerg Med. 2020 Oct 24;2020:8895785. doi: 10.1155/2020/8895785. eCollection 2020. PMID: 33163240; PMCID: PMC7605928.
Copy Download .nbib Format: NLM
Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy.

Frontiers in pharmacology

Li L, Li X, Xia Y, Chu Y, Zhong H, Li J, Liang P, Bu Y, Zhao R, Liao Y, Yang P, Lu X, Jiang S.
PMID: 32547394
Front Pharmacol. 2020 May 29;11:786. doi: 10.3389/fphar.2020.00786. eCollection 2020.

Continuous Renal Replacement Therapy (CRRT) is more and more widely used in patients for various indications recent years. It is still intricate for clinicians to decide a suitable empiric antimicrobial dosing for patients receiving CRRT. Inappropriate doses of antimicrobial...

Cite
Li L, Li X, Xia Y, et al. Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy. Front Pharmacol. 2020;11:786doi: 10.3389/fphar.2020.00786.
Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy. Frontiers in pharmacology, 11786. https://doi.org/10.3389/fphar.2020.00786
Li, Lu, et al. "Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy." Frontiers in pharmacology vol. 11 (2020): 786. doi: https://doi.org/10.3389/fphar.2020.00786
Li L, Li X, Xia Y, Chu Y, Zhong H, Li J, Liang P, Bu Y, Zhao R, Liao Y, Yang P, Lu X, Jiang S. Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy. Front Pharmacol. 2020 May 29;11:786. doi: 10.3389/fphar.2020.00786. eCollection 2020. PMID: 32547394; PMCID: PMC7273837.
Copy Download .nbib Format: NLM
Interplay of OpdP Porin and Chromosomal Carbapenemases in the Determination of Carbapenem Resistance/Susceptibility in Pseudomonas aeruginosa.

Microbiology spectrum

Atrissi J, Milan A, Bressan R, Lucafò M, Petix V, Busetti M, Dolzani L, Lagatolla C.
PMID: 34585948
Microbiol Spectr. 2021 Oct 31;9(2):e0118621. doi: 10.1128/Spectrum.01186-21. Epub 2021 Sep 29.

Carbapenem resistance in Pseudomonas aeruginosa strains responsible for chronic lung infections in cystic fibrosis (CF) patients is mainly due to loss of the OprD protein and, limited to meropenem and doripenem, to overexpression of efflux pumps. However, recent reports...

Cite
Atrissi J, Milan A, Bressan R, et al. Interplay of OpdP Porin and Chromosomal Carbapenemases in the Determination of Carbapenem Resistance/Susceptibility in Pseudomonas aeruginosa. Microbiol Spectr. 2021;9(2):e0118621doi: 10.1128/Spectrum.01186-21.
Atrissi, J., Milan, A., Bressan, R., Lucafò, M., Petix, V., Busetti, M., Dolzani, L., & Lagatolla, C. (2021). Interplay of OpdP Porin and Chromosomal Carbapenemases in the Determination of Carbapenem Resistance/Susceptibility in Pseudomonas aeruginosa. Microbiology spectrum, 9(2), e0118621. https://doi.org/10.1128/Spectrum.01186-21
Atrissi, Jad, et al. "Interplay of OpdP Porin and Chromosomal Carbapenemases in the Determination of Carbapenem Resistance/Susceptibility in Pseudomonas aeruginosa." Microbiology spectrum vol. 9,2 (2021): e0118621. doi: https://doi.org/10.1128/Spectrum.01186-21
Atrissi J, Milan A, Bressan R, Lucafò M, Petix V, Busetti M, Dolzani L, Lagatolla C. Interplay of OpdP Porin and Chromosomal Carbapenemases in the Determination of Carbapenem Resistance/Susceptibility in Pseudomonas aeruginosa. Microbiol Spectr. 2021 Oct 31;9(2):e0118621. doi: 10.1128/Spectrum.01186-21. Epub 2021 Sep 29. PMID: 34585948; PMCID: PMC8557820.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 104 entries